ClinicalTrials.gg
RecruitingNCT06713369AZD5305Updated Nov 12, 2026

AZD5305 hADME in Patients With Advanced Solid Malignancies

A Phase 1 interventional study of Saruparib (AZD5305) and [14C]-AZD5305 microtracer in Locally Advanced or Metastatic Solid Tumor, sponsored by AstraZeneca. Recruiting at 2 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Nov 12, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies in Neoplasm Metastasis by AstraZeneca — 6 open to participants now, 23 under way, 14 of them phase 3. Neoplasm Metastasis · AstraZeneca.

Planned enrollment
53rd of 55
8 · median 102
Started
2025
with 3 others
Phase 1
19 of 60
1 open now
Primary completion
2026-12
later than 14 of 22 live
Registered
56th of 60
by date

Among the 60 studies in Neoplasm Metastasis by AstraZeneca, this one is the 53rd largest by planned enrollment of the 55 interventional ones that give a count, is one of 4 that started in 2025, is one of 19 in phase 1, reaches primary completion later than 14 of the 22 other live ones, and was the 56th registered.

Neoplasm Metastasis

4,048 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

6 of the 60 studies in Neoplasm Metastasis by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 691 Neoplasm Metastasis studies recruiting now, 538 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Neoplasm Metastasis by AstraZeneca, or all of them as a file.
02

Study summary

This Phase I, open-label study aims to study to absolute bioavailability of Saruparib (AZD5305) and the absorption, distribution, metabolism and excretion (ADME) of [14C]-Saruparib in patients with advanced solid malignancies.

This will be done on an inpatient basis in 2 parts (single-dose oral administration with radiolabeled microtracer in Part A, single-dose IV radiolabeled administration in Part B) during which samples will be obtained of plasma, urine, feces and vomitus (where applicable).

Read the detailed description

This is an open-label, 2-part study in participants with advanced solid malignancies and will be conducted at multiple study sites.

Participants will be assessed for study eligibility prior to admission to the study site during a 28-day screening period. Participants will take part in both Parts A and B of the study.

Part A will assess the absolute bioavailability and evaluate the PK parameters of oral Saruparib and a radiolabelled IV microdose of [14C]-Saruparib

Participants will be admitted to the study site pre-dose of Part A and will remain resident at the study site for PK sampling and safety assessments.

A washout period will be observed between doses of Saruparib in Parts A and B.

Part B will assess the ADME of oral [14C]-Saruparib. Participants will be readmitted to the study site for Part B and will remain resident at the study site for excreta (urine, faeces, and any vomitus) collections, PK sampling, and safety assessments. Participants may be discharged from the study site prior to the last indicated day if both the following discharge criteria are met:

  1. ≥ 90% mass balance recovery, and
  2. \< 1% of the total radioactive dose is recovered in combined excreta (urine and faeces) in 2 consecutive 24-hour periods.

Participants will return to the study site for a Follow-up Visit after the last dose of Saruparib which will include routine safety assessments. After the completion of Parts A and B, and following the Follow-up Visit, participants may be allowed further access to Saruparib.

Additional safety data collection will be conducted.

03

Conditions studied

  • Locally Advanced or Metastatic Solid Tumor

Keywords

  • hADME
  • saruparib
  • AZD5305
  • advanced solid tumour / tumor
  • neoplasm
04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥ 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place), at the time of signing the ICF.
  2. or cytologically documented, locally advanced or solid tumour, excluding lymphoma, for which standard therapy does not exist or has proven ineffective or intolerable.
  3. performance status of 0 or 1 with no deterioration over the 2 weeks prior to dosing.
  4. Predicted ≥ 12 weeks.
  5. Adequate organ and marrow function as defined in the protocol
  6. Willingness and ability to comply with study and follow-up procedures.
  7. Able and willing to stay in hospital for specified residential periods following administration of Saruparib/[14C]-Saruparib
  8. Regular bowel movements
  9. Body weight within normal range specified in protocol
  10. use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies Reproduction
  11. Capable of giving signed which includes compliance with the requirements and restrictions listed in the ICF and in the protocol

Exclusion criteria

Exclusion Criteria:

  1. Participants with a history of MDS/AML or with features suggestive of MDS/AML (as determined by prior diagnostic investigation). Specific screening for MDS/AML is not required.
  2. Participants with any known predisposition to bleeding
  3. Any history of persisting severe cytopenia due to any cause
  4. nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of Saruparib.
  5. History of another primary , with some exceptions
  6. Persistent toxicities ( Grade ≥ 2), excluding alopecia and peripheral neuropathy, caused by previous anticancer therapy.
  7. Spinal cord compression or for at least 4 weeks prior to start of study intervention unless asymptomatic and stable
  8. Abnormal cardiac function exclusions or cardiovascular disease
  9. History of arrhythmia
  10. Active (positive HBsAg result) or .
  11. Evidence of active and uncontrolled infection.
  12. Active tuberculosis infection
  13. Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study.
  14. As judged by the investigator, any other evidence of diseases (such as severe or uncontrolled systemic diseases or active uncontrolled infections which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or would jeopardise compliance with the protocol.
  15. Any prior treatment with Saruparib.
  16. Other anticancer therapy (chemotherapy, immunotherapy, hormonal anticancer therapy, radiotherapy [except for palliative local radiotherapy]), biological therapy or other novel agent is not permitted until the last PK sampling is completed.
  17. Palliative radiotherapy with a limited field of radiation within 2 weeks or with wide field of radiation or to more than 30% of the bone marrow within 4 weeks before the first dose of study intervention
  18. Concomitant use of medications or herbal supplements known to be strong inhibitors or inducers
  19. Concomitant use of drugs that are known to prolong or shorten and have a known risk of Torsades de Pointes
  20. Participants who have participated in another absorption, distribution, metabolism, and excretion study within 1 year prior to screening.
  21. Participation in another clinical study with a study intervention administered in the last 1 month or 5 half-lives prior to dosing, whichever is longer.
  22. Participants with a known to Saruparib or any of the of the product.
  23. Participants who have been administered any amount of a [14C]-labelled compound within the last 12 months.
  24. Use of tobacco- or nicotine-containing products or alcohol may be exclusionary
  25. Poor peripheral venous access (venous access via a port will be permitted).
  26. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  27. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
  28. Previous enrolment in the present study.
  29. For female participants only: currently pregnant (confirmed with positive pregnancy test) or planning to become pregnant, breast-feeding, or intending to donate/retrieve ova before 6 months after the last dose of Saruparib.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    Primary Treatment Arm - AZD5305

    Part A will assess absolute bioavailability via oral administration of Saruparib (AZD5305) and IV \[14C\]-saruparib microtracer. Part B will assess ADME via IV \[14C\]-saruparib administration

    Drug: Saruparib (AZD5305) · Drug: [14C]-AZD5305 microtracer · Drug: [14C]-AZD5305 (therapeutic dose)

Interventions

  • PARP-inhibitor

    Also known as: Saruparib

  • Drug[14C]-AZD5305 microtracer

    IV radiolabeled microtracer

    Also known as: IV [14C]-Saruparib microtracer

  • IV radiolabeled PARP inhibitor

    Also known as: IV [14C]-Saruparib (therapeutic dose)

06

What researchers measure

Primary outcomes

  1. Absolute bioavailability (F) of Saruparib

    Absolute bioavailability (F) of Saruparib

    Time frame: Day 4

  2. Total radioactivity recovery in urine and faeces

    Total radioactivity recovery in urine and faeces

    Time frame: Day 8

  3. Pharmacokinetics of Saruparib(Part B)

    AUCinf

    Time frame: Day 8

  4. PK parameters characterized by AUCinf

    AUCinf

    Time frame: Day 4

  5. Ratio of AUCinf of plasma Saruparib relative to AUCinf of metabolite

    Ratio of AUCinf of plasma Saruparib relative to AUCinf of metabolite

    Time frame: Day 4

  6. Mass balance parameters as characterized by amount excreted and cumulative amount excreted in urine, faeces and total (urine and faeces combined)

    Cumulative amount excreted in urine, faeces and total (urine and faeces combined)

    Time frame: Day 8

  7. Amount excreted and cumulative amount excreted in urine, faeces and total (urine and faeces combined) expressed as a percentage of the administered dose

    Amount excreted and cumulative amount excreted in urine, faeces and total (urine and faeces combined) expressed as a percentage of the administered dose.

    Time frame: Day 8

  8. Pharmacokinetics of Saruparib(Part B)

    AUClast

    Time frame: Day 8

  9. Pharmacokinetics of Saruparib(Part B)

    Cmax

    Time frame: Day 8

  10. Pharmacokinetics of Saruparib(Part B)

    tmax

    Time frame: Day 8

  11. Pharmacokinetics of Saruparib(Part B)

    t1/2(lambda)z

    Time frame: Day 8

  12. Pharmacokinetics of Saruparib(Part B)

    Ratio of AUCinf of plasma Saruparib relative to AUCinf of plasma total radioactivity

    Time frame: Day 8

  13. Pharmacokinetics of Saruparib(Part B)

    Ratio of AUCinf of whole blood total radioactivity relative to AUCinf of plasma total radioactivity

    Time frame: Day 8

  14. PK parameters characterized by AUClast

    AUClast

    Time frame: Day 4

  15. PK parameters characterized by Cmax

    Cmax

    Time frame: Day 4

  16. PK parameters characterized by tmax

    tmax

    Time frame: Day 4

  17. PK parameters characterized by t1/2(lambda)z

    t1/2(lambda)z

    Time frame: Day 4

Secondary outcomes

  1. Metabolic profiling of a single oral dose of [14C]-Saruparib (Part B)

    Determining mass balance parameters following oral administration of a therapeutic dose containing 20uCi of 14C-AZD5305 followed by metabolite profiling and identification in plasma, urine, and feces to quantify the 14C-AZD5305 related material in each matrix to satisfy MIST considerations.

    Time frame: Day 8

  2. Characterize the safety of Saruparib in participants with advanced solid malignancies by incidence and severity of AEs, laboratory abnormalities, 12-lead ECG abnormalities, vital signs abnormalities, physical examination findings

    incidence and severity of AEs, -incidence of laboratory abnormalities (based on hematology, clinical chemistry, and urinalysis test results), -12-lead ECG abnormalities, vital signs abnormalities, physical examination findings

    Time frame: Day 14

07

Study locations

2 of 2 sites recruiting
  • Research Site
    Liverpool, L7 8YA, United Kingdom
    Recruiting
  • Research Site
    Manchester, M20 4BX, United Kingdom
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.

Of 288 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 20 months is below that.

Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Oct 2026 → Dec 2026 and completion Oct 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2024
First posted
Dec 3, 2024
StartActual
Apr 2, 2025
Primary completionEst.
Dec 31, 2026was Oct 2026
CompletionEst.
Feb 8, 2027was Oct 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 2, 2026→Dec 31, 2026
Nov 12, 2026
Study completion
Oct 2, 2026→Feb 8, 2027
Nov 12, 2026
Eligibility
4 exclusion criteria edited
What changed in the criteria
Exclusion criteria
  • EditedPersistent toxicities (CTCAE Grade ≥ 2), excluding alopecia and peripheral neuropathy, caused by previous anticancer therapy.
  • EditedAny prior treatment with a PARP inhibitor or platinum chemotherapySaruparib.
  • EditedConcomitant use of medications or herbal supplements known to be CYP3A4 strong and moderate inhibitors or inducers
  • EditedParticipation in another clinical study with a study intervention administered in the last 3 months1 month or 5 half-lives prior to dosing, whichever is longer.
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Oct 2, 2026→Dec 31, 2026
    Study completion Oct 2, 2026→Feb 8, 2027
    Eligibility 4 exclusion criteria edited
    What changed in the criteria
    Exclusion criteria
    • EditedPersistent toxicities (CTCAE Grade ≥ 2), excluding alopecia and peripheral neuropathy, caused by previous anticancer therapy.
    • EditedAny prior treatment with a PARP inhibitor or platinum chemotherapySaruparib.
    • EditedConcomitant use of medications or herbal supplements known to be CYP3A4 strong and moderate inhibitors or inducers
    • EditedParticipation in another clinical study with a study intervention administered in the last 3 months1 month or 5 half-lives prior to dosing, whichever is longer.
    + 2 other changes: verification date and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06713369
Lead sponsor
AstraZeneca
Collaborators
Fortrea
Responsible party
Sponsor
First posted
Dec 3, 2024
Start date
Apr 2, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Feb 8, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD5305

Start the discussion